MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
Seeking Alpha / 1 hour ago 1 Views
Seeking Alpha / 1 hour ago 1 Views
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026
Comments